Fig. 3

The impacts of COX-2 inhibitor celecoxib on megakaryopoiesis and thrombopoiesis in Meg01 cells. Meg01 cells were treated with different concentrations of COX-2 inhibitor celecoxib in vitro. A The relative count of CD41⁺CD61⁺ megakaryocytes in Meg01 cells. Flow cytometry dot plots showed the percentages and gates. B Percentages of CD62P⁺ cells in CD41⁺CD61⁺ megakaryocytes. Flow cytometry dot plots showed the percentages and gates for CD62P⁺ cells in CD41⁺CD61⁺ megakaryocytes. C Mean fluorescence intensity (MFI) of CD41 in CD41⁺CD61⁺ megakaryocytes. Histogram plots showed the fluorescence intensity of CD41 in flow cytometry. D Percentages of polyploid cells in CD41⁺CD61⁺ megakaryocytes. Histogram plots showed the percentages and gates for polyploid cells (N > 4) in CD41⁺CD61⁺ megakaryocytes. E Percentages of Annexin V⁺ apoptotic cells in CD41⁺CD61⁺ megakaryocytes. Flow cytometry dot plots showed the percentages and gates for Annexin V⁺ cells in CD41⁺CD61⁺ megakaryocytes. F Relative mRNA expression of TNFSF10, GATA1 and NFE2 of Meg01 cells. G Western blot plot of the GATA1 expression in Meg01 cells. Tubulin was set as internal reference. H Representative light microscopy plot of Meg01 cells without PMA stimulation. I Immunofluorescence staining of PMA-stimulated Meg01 cells. Hoechst was used to identify nucleus. J Relative count of CD41⁺ platelet granules. *P < 0.05, **P < 0.01, ***P < 0.001